Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury.
作者信息
Sise Meghan E, Baggett Meridale V, Shepard Jo-Anne O, Stevens Jacob S, Rhee Eugene P
机构信息
From the Departments of Medicine (M.E.S., M.V.B., E.P.R.) and Radiology (J.-A.O.S.), Massachusetts General Hospital, and the Departments of Medicine (M.E.S., M.V.B., E.P.R.) and Radiology (J.-A.O.S.), Harvard Medical School - both in Boston; and the Department of Medicine, Columbia University Irving Medical Center, and the Department of Medicine, Vagelos College of Physicians and Surgeons - both in New York (J.S.S.).
出版信息
N Engl J Med. 2020 May 28;382(22):2147-2156. doi: 10.1056/NEJMcpc2002418. Epub 2020 May 13.
Abstract
摘要
相似文献
1
Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury.病例17 - 2020：一名患有新冠病毒病和急性肾损伤的68岁男性。
N Engl J Med. 2020 May 28;382(22):2147-2156. doi: 10.1056/NEJMcpc2002418. Epub 2020 May 13.
2
Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?我们用瑞德西韦（一种老药新包装）找到了治疗新冠病毒肺炎的万灵药了吗？
J R Coll Physicians Edinb. 2020 Jun;50(2):159-161. doi: 10.4997/JRCPE.2020.217.
3
Psychopharmacology of COVID-19.新型冠状病毒肺炎的精神药理学。
Psychosomatics. 2020 Sep-Oct;61(5):411-427. doi: 10.1016/j.psym.2020.05.006. Epub 2020 May 18.
4
Using "old" medications to fight new COVID-19: Re-purposing with a purpose.使用“旧”药物对抗新型冠状病毒肺炎：有目的地重新利用
J Mol Cell Cardiol. 2020 Sep;146:41-42. doi: 10.1016/j.yjmcc.2020.07.005. Epub 2020 Jul 18.
5
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.新型冠状病毒治疗药物的安全性、临床应用和抗病毒研究概述。
J Infect Public Health. 2020 Oct;13(10):1405-1414. doi: 10.1016/j.jiph.2020.07.004. Epub 2020 Jul 13.
6
Treatment of SARS-CoV-2: How far have we reached?新型冠状病毒肺炎的治疗：我们已经取得了多大进展？
Drug Discov Ther. 2020 May 6;14(2):67-72. doi: 10.5582/ddt.2020.03008. Epub 2020 Apr 25.
7
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.支持瑞德西韦治疗新型冠状病毒感染的论据。
Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.
8
COVID-19: Rescue by transcriptional inhibition.新型冠状病毒肺炎：通过转录抑制进行挽救。
Sci Adv. 2020 Jul 1;6(27). doi: 10.1126/sciadv.abc6891. Print 2020 Jul.
9
Treatment options for COVID-19: The reality and challenges.治疗 COVID-19 的选择：现实与挑战。
J Microbiol Immunol Infect. 2020 Jun;53(3):436-443. doi: 10.1016/j.jmii.2020.03.034. Epub 2020 Apr 4.
10
Treatments for COVID-19: where are we now?2019冠状病毒病的治疗方法：我们目前处于什么阶段？
Br J Community Nurs. 2020 Aug 2;25(8):412-413. doi: 10.12968/bjcn.2020.25.8.412.
引用本文的文献
1
Building a Community of Medical Learning - A Century of Case Records of the Massachusetts General Hospital in the .建立医学学习社区——麻省总医院一个世纪的病例记录
N Engl J Med. 2024 Sep 5;391(9):858-863. doi: 10.1056/NEJMms2405389.
2
Nafamostat Mesylate for the Hypercoagulable State of SARS-CoV-2 With Renal Replacement Therapy: A Case Report.甲磺酸萘莫司他用于接受肾脏替代治疗的新型冠状病毒肺炎高凝状态：一例报告
Cureus. 2024 Jan 20;16(1):e52641. doi: 10.7759/cureus.52641. eCollection 2024 Jan.
3
Our Experience with SARS-CoV-2 Infection and Acute Kidney Injury: Results from a Single-Center Retrospective Observational Study.我们对新型冠状病毒2型感染与急性肾损伤的经验：一项单中心回顾性观察研究的结果
Healthcare (Basel). 2023 Aug 26;11(17):2402. doi: 10.3390/healthcare11172402.
4
Extracardiac Prothrombotic Effects of COVID-19.COVID-19 的心脏外促血栓形成效应。
Heart Fail Clin. 2023 Apr;19(2):213-220. doi: 10.1016/j.hfc.2022.08.008.
5
Dysrhythmias associated with COVID-19: Review and management considerations.与 COVID-19 相关的心律失常：综述及处理要点。
Am J Emerg Med. 2023 Feb;64:161-168. doi: 10.1016/j.ajem.2022.12.004. Epub 2022 Dec 5.
6
SARS-CoV-2-Infection (COVID-19): Clinical Course, Viral Acute Respiratory Distress Syndrome (ARDS) and Cause(s) of Death.SARS-CoV-2 感染（COVID-19）：临床病程、病毒引起的急性呼吸窘迫综合征（ARDS）和死亡原因。
Med Sci (Basel). 2022 Oct 10;10(4):58. doi: 10.3390/medsci10040058.
7
Extracardiac Prothrombotic Effects of COVID-19.COVID-19 的心脏外促血栓形成效应。
Cardiol Clin. 2022 Aug;40(3):337-344. doi: 10.1016/j.ccl.2022.03.008. Epub 2022 Mar 29.
8
Potential role of biochemical markers in the prognosis of COVID-19 patients.生化标志物在COVID-19患者预后中的潜在作用。
SAGE Open Med. 2022 Jul 5;10:20503121221108613. doi: 10.1177/20503121221108613. eCollection 2022.
9
COVID-19 presenting with myocardial infarction with nonobstructive coronary arteries.新型冠状病毒肺炎表现为非阻塞性冠状动脉心肌梗死。
Proc (Bayl Univ Med Cent). 2022 Apr 8;35(4):514-516. doi: 10.1080/08998280.2022.2057158. eCollection 2022.
10
COVID-19 and Acute Kidney Injury: A Systematic Review.新型冠状病毒肺炎与急性肾损伤：一项系统综述
Front Med (Lausanne). 2022 Apr 4;9:705908. doi: 10.3389/fmed.2022.705908. eCollection 2022.
本文引用的文献
1
Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection.人类肾脏是新型严重急性呼吸综合征冠状病毒 2 感染的靶器官。
Nat Commun. 2021 May 4;12(1):2506. doi: 10.1038/s41467-021-22781-1.
2
Single-cell analysis of angiotensin-converting enzyme II expression in human kidneys and bladders reveals a potential route of 2019 novel coronavirus infection.单细胞分析人类肾脏和膀胱中血管紧张素转化酶 2 的表达，揭示了 2019 年新型冠状病毒感染的潜在途径。
Chin Med J (Engl). 2021 Apr 20;134(8):935-943. doi: 10.1097/CM9.0000000000001439.
3
COVID-19 Complicated by Acute Pulmonary Embolism.新型冠状病毒肺炎合并急性肺栓塞
Radiol Cardiothorac Imaging. 2020 Mar 16;2(2):e200067. doi: 10.1148/ryct.2020200067. eCollection 2020 Apr.
4
ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Infection in COVID-19 Patients.血管紧张素转换酶2（ACE2）在肾脏和睾丸中的表达可能导致COVID-19患者的肾脏和睾丸感染。
Front Med (Lausanne). 2021 Jan 13;7:563893. doi: 10.3389/fmed.2020.563893. eCollection 2020.
5
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].羟氯喹治疗中度新型冠状病毒肺炎患者的一项试点研究
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219. doi: 10.3785/j.issn.1008-9292.2020.03.03.
6
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.法匹拉韦治疗新型冠状病毒肺炎的实验性治疗：一项开放标签对照研究。
Engineering (Beijing). 2020 Oct;6(10):1192-1198. doi: 10.1016/j.eng.2020.03.007. Epub 2020 Mar 18.
7
SARS-CoV-2 can be detected in urine, blood, anal swabs, and oropharyngeal swabs specimens.SARS-CoV-2 可在尿液、血液、肛拭子和咽拭子标本中检测到。
J Med Virol. 2020 Sep;92(9):1676-1680. doi: 10.1002/jmv.25936. Epub 2020 Apr 30.
8
Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China.中国 26 例 COVID-19 死亡患者的肾脏组织病理分析。
Kidney Int. 2020 Jul;98(1):219-227. doi: 10.1016/j.kint.2020.04.003. Epub 2020 Apr 9.
9
Compassionate Use of Remdesivir for Patients with Severe Covid-19.瑞德西韦在治疗重症 COVID-19 患者中的同情使用。
N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10.
10
Kidney disease is associated with in-hospital death of patients with COVID-19.肾病与 COVID-19 患者住院期间的死亡相关。
Kidney Int. 2020 May;97(5):829-838. doi: 10.1016/j.kint.2020.03.005. Epub 2020 Mar 20.
Zotero 插件